US2005239151A1PendingUtilityA1

Method of detecting an antibody in a liquid sample

45
Assignee: IPSEN HANS-HENRIKPriority: Jun 24, 1998Filed: Jun 23, 2005Published: Oct 27, 2005
Est. expiryJun 24, 2018(expired)· nominal 20-yr term from priority
Inventors:Hans-Henrik IpsenNiels JohansenRikke MorkebergSoren BogestrandTine Charlotte Beck
G01N 33/54306G01N 33/577G01N 2800/24Y10S424/809Y10S436/824Y10S530/862Y10S436/825G01N 33/585G01N 33/54313Y10S424/805Y10S436/804G01N 33/6854Y10S530/866
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a method of evaluating the immunological status of a subject comprising the steps of 1) determining the content of an antibody in a liquid sample from the subject using an immunoassay, wherein the reaction between the antibody of the sample and a ligand in the form of an antigen, an antibody or a hapten, the ligand being directed to the Fab region of the sample antibody, is carried out in the presence of other constituents of the sample to obtain a measurement 1, 2) determining the content of an antibody in the liquid sample using an immunoassay, wherein the reaction between the antibody of the sample and a ligand in the form of an antigen, an antibody or a hapten, the ligand being directed to the Fab region of the sample antibody, is carried out in the absence of other constituents of the sample to obtain a measurement 2, and 3) interrelating measurements 1 and 2 to express the interference and using the interference as a parameter or evaluating the immunological status of the subject.

Claims

exact text as granted — not AI-modified
1 - 37 . (canceled)  
   
   
       38 : A method of detecting and/or quantifying an antibody in a liquid sample comprising the steps of: 
 (o′) providing a mixture of a liquid phase and a two-component solid phase complex composed of (i) the antibody of the sample, and (ii) a reactant antibody directed against the sample antibody, the reactant antibody being bound to a solid particle;    (p′) separating the two-component solid phase complex from the liquid phase;    (q′) washing the separated two-component solid phase complex to remove non-complex bound compounds;    (r′) adding to the washed two-component solid phase complex a solution of (iii) a ligand in the form of an antigen, an antibody or a hapten, which is optionally labeled, to form a three-compound solid phase complex;    (s′) optionally adding to the three-component solid phase complex a solution of (iv) a label compound to form a four-component solid phase complex;    (t′) separating the three- or four-component solid phase complex obtained in step (r′) or (s′), respectively, from the solution;    (u′) washing the separated multi-component solid phase complex to remove non-complex bound compounds; and    (v′) performing a detection/measurement of the washed labeled multi-component complex.    
   
   
       39 : A method of detecting and/or quantifying an antibody in a liquid sample comprising the steps of: 
 (o) providing a mixture of a liquid phase and a two-component solid phase complex composed of (i) the antibody of the sample, and (ii) a reactant antibody directed against the sample antibody, the reactant antibody being bound to a solid particle;    (p) separating the two-component solid phase complex from the liquid phase;    (q) washing the separated two-component, solid phase complex to remove non-complex bound compounds;    (r) adding to the washed two-component solid phase complex a solution of (iii) a ligand in the form of an antigen, an antibody or a hapten, which is bound to biotin or a functional derivative thereof, to form a three-component solid phase complex;    (s) adding to the three-component solid phase complex a solution of (iv) a chemiluminescent compound covalently bound to avidin, streptavidin or a functional derivative thereof to form a four-component solid phase complex;    (t) separating the four-component solid phase complex from the solution;    (u) washing the separated four-component solid phase complex to remove non-complex bound compound (iv); and    (v) initiating a chemiluminescent reaction in the washed four-component solid phase complex and detecting/measuring the resulting chemiluminescence, if any.    
   
   
       40 : A method of detecting and/or quantifying an antibody in a liquid sample comprising the steps of: 
 (o″) providing a mixture of a liquid phase and a two-component solid phase complex composed of (i) the antibody of the sample, and (ii) a reactant antibody directed against the sample antibody, the reactant antibody being bound to a solid paramagnetic particle;    (p″) separating magnetically the two-component solid phase complex from the liquid phase;    (q″) washing the separated two-component solid phase complex to remove non-complex bound compounds;    (r″) adding to the washed two-component solid phase complex a solution of (iii) a ligand in the form of an antigen, an antibody or a hapten, which is bound to biotin or a functional derivative thereof, to form a three-component solid phase complex;    (s″) adding to the three-component solid phase complex a solution of (iv) a chemiluminescent compound covalently bound to avidin, streptavidin or a functional derivative thereof to form a four-component solid phase complex;    (t″) separating magnetically the four-component solid phase complex from the solution;    (u″) washing the separated four-component solid phase complex to remove non-complex bound compound (iv); and    (v″) initiating a chemiluminescent reaction in the washed four-component solid phase complex and detecting/measuring the resulting chemiluminescence, if any.    
   
   
       41 : A method according to  claim 39 , wherein the chemiluminescent compound is an acridinium compound.  
   
   
       42 : A method according to  claim 40 , wherein the chemiluminescent compound is an acridinium compound.  
   
   
       43 : A method according to  claim 38 , wherein component (iii) of step (r′), and component (iv) of step (s′), respectively, are added in one operation.  
   
   
       44 : A method according to  claim 39 , wherein component (iii) of step (r) and component (iv) of step (s) respectively, are added in one operation.  
   
   
       45 : A method according to  claim 40 , wherein component (iii) of step (r″) and component (iv) of step (s″), respectively, are added in one operation.  
   
   
       46 : A method according to  claim 39 , wherein the three-component solid phase complex formed in step (r) prior to subjecting it to step(s) is washed to remove non-complex bound compounds.  
   
   
       47 : A method according to  claim 40 , wherein the three-component solid phase complex formed in step (r″) prior to subjecting it to step (s″), is washed to remove non-complex bound compounds.  
   
   
       48 : A method of evaluating and/or predicting the effect of a Specific Allergy Vaccination treatment comprising the steps of: 
 (x′) determining the content of an antibody in a liquid sample using the method of  claim 38;     (y′) determining the content of the said antibody using the following assay:    (ya′) providing a mixture of a liquid phase and a three-component solid phase complex composed of (i) the antibody of the sample, (ii) a reactant antibody directed against the sample antibody, the reactant antibody being bound to a solid particle, (iii) a ligand in the form of an antigen, an antibody or a hapten which is labeled or bound to (iv) a label compound, to form a multi-component solid phase complex,    (yb′) separating the multi-component solid phase complex from the liquid phase,    (yc′) washing the separated multi-component solid phase to remove non-complex bound compounds, and    (yd′) performing a detection/measurement of the washed labeled multi-component complex, and    (z′) comparing the measurements obtained in step (x′) and step (y′) and using the comparison to evaluate and/or predict the effect of the Specific Allergy Vaccination treatment.    
   
   
       49 : A method of evaluating and/or predicting the effect of a Specific Allergy Vaccination treatment comprising the steps of: 
 (x) determining the content of an antibody in a liquid sample using the method of  claim 39 ,    (y) determining the content of the said antibody using the following assay:    (ya) providing a mixture of a liquid phase and a four-component solid phase complex composed of (i) the antibody of the sample, (ii) a reactant antibody directed against the sample antibody, the reactant antibody being bound to a solid particle, (iii) a ligand in the form of an antigen, an antibody or a hapten, which is bound to biotin or a functional derivative thereof, and (iv) a chemiluminescent compound covalently bound to avidin, streptavidin or a functional derivative thereof, to form a four-component solid phase complex,    (yb) separating the four-component solid phase complex from the liquid phase,    (yc) washing the separated four-component solid phase to remove non-complex bound compounds,    (yd) initiating a chemiluminescent reaction in the washed four-component solid phase complex and measuring the resulting chemiluminescence, if any, and    (z) comparing the measurements obtained in step (x) and step (y) and using the comparison to evaluate and/or predict the effect of the Specific Allergy Vaccination treatment.    
   
   
       50 : A method of evaluating and/or predicting the effect of a Specific Allergy Vaccination treatment comprising the steps of: 
 (x″) determining the content of an antibody in a liquid sample using the method of  claim 40 ,    (y″) determining the content of the said antibody using the following assay:    (ya″) providing a mixture of a liquid phase and a four-component solid phase complex composed of (i) the antibody of the sample, (ii) a reactant antibody directed against the sample antibody, the reactant antibody being bound to a solid paramagnetic particle, (iii) a ligand in the form of an antigen, an antibody or a hapten, which is bound to biotin or a functional derivative thereof, and (iv) a chemiluminescent compound covalently bound to avidin, streptavidin or a functional derivative thereof, to form a four-component solid phase complex,    (yb″) separating magnetically the four-component solid phase complex from the liquid phase,    (yc″) washing the separated four-component solid phase to remove non-complex bound compounds,    (yd″) initiating a chemiluminescent reaction in the washed four-component solid phase complex and measuring the resulting chemiluminescent, if any, and    (z″) comparing the measurements obtained in step (x″) and step (y″) and using the comparison to evaluate and/or predict the effect of the Specific Allergy Vaccination treatment.    
   
   
       51 : A method according to  claim 48 , wherein step (ya′) is carried out by mixing components (i) and (ii), then adding component (iii), and finally adding component (iv), if added.  
   
   
       52 : A method according to  claim 49 , wherein step (ya) is carried out by mixing components (i) and (ii), then adding component (iii), and finally adding component (iv), if added.  
   
   
       53 : A method according to  claim 50  wherein step (ya″) is carried out by mixing components (i) and (ii), then adding component (iii), and finally adding component (iv), if added.  
   
   
       54 : A method according to  claim 48 , wherein step (ya′) is carried out by mixing components (i), (ii) and (iii), and then adding component (iv), if added.  
   
   
       55 : A method according to  claim 49 , wherein step (ya) is carried out by mixing components (i), (ii) and (iii), and then adding component (iv), if added.  
   
   
       56 : A method according to  claim 50 , wherein step (ya″), is carried out by mixing components (i), (ii) and (iii), and then adding component (iv), if added.  
   
   
       57 : A method according to  claim 48 , wherein the comparison of step (z′) is carried out by calculating the ratio of the measurements obtained in the two said steps.  
   
   
       58 : A method according to  claim 49 , wherein the comparison of step (z) is carried out by calculating the ratio of the measurements obtained in the two said steps.  
   
   
       59 : A method according to  claim 50 , wherein the comparison of step (z″) is carried out by calculating the ratio of the measurements obtained in the two said steps.  
   
   
       60 : A method according to  claim 48 , wherein the comparison of step (z′) is carried out at a number of points in time at the start of and during the treatment period, and that any temporal change, which may be observed, is used as a basis for evaluating and/or predicting the effect of the treatment.  
   
   
       61 : A method according to  claim 49 , wherein the comparison of step (z) is carried out at a number of points in time at the start of and during the treatment period, and that any temporal change, which may be observed, is used as a basis for evaluating and/or predicting the effect of the treatment.  
   
   
       62 : A method according to  claim 50 , wherein the comparison of step (z″) is carried out at a number of points in time at the start of and during the treatment period, and that any temporal change, which may be observed, is used as a basis for evaluating and/or predicting the effect of the treatment.  
   
   
       63 : A method according to  claim 38 , wherein the label compound is selected from the group consisting of a luminescent label, a chemiluminescent label, an enzyme label, a radioactivity label, a fluorescent label and an absorbance label.  
   
   
       64 : A method according to  claim 38 , wherein the labeled ligand is labeled by a radioactive atom.  
   
   
       65 : A method according to  claim 38 , wherein the separation of the solid phase complex from the liquid phase is carried out by a member selected from the group consisting of magnetic separation, filtration, sedimentation, centrifugation, chromatography and column chromatography.  
   
   
       66 : A method of evaluating the effect of allergy treatment of a subject comprising the steps of: 
 A) determining the content of the said antibody using the following assay protocol (assay A);    (Aa) mixing (i) the antibody of the sample, (ii) an antibody directed against the Fc region of the sample antibody, the reactant antibody being bound to a solid carrier and (iii) a ligand in the form of an antigen, an antibody or a hapten, the ligand being directed to the Fab region of the sample antibody, to form a mixture of a three-component solid phase complex and a liquid phase,    (Ab) contacting the three-component complex with (iv) a label compound to form a mixture of a four-component complex and a liquid phase,    (Ac) washing the four-component solid phase to remove non-complex bound compounds,    (Ad) performing a detection/measurement of the washed labeled four-component complex to obtain a measurement A;    (E) using measurement A as a parameter for evaluating the effect of the treatment.    
   
   
       67 : A method of evaluating the effect of allergy treatment of a subject comprising the steps of: 
 (C) determining the content of the said antibody using the following assay protocol (assay C);    (Ca) mixing (i) the antibody of the sample, (ii) an antibody directed against the Fc region of the sample antibody, the reactant antibody being bound to a solid carrier and (iii) a labeled ligand in the form of an antigen, an antibody or a hapten, the ligand being directed to the Fab region of the sample antibody, to form a mixture of three-component solid phase complex and a liquid phase,    (Cb) washing the three-component solid phase to remove non-complex bound compounds,    (Cc) performing a detection/measurement of the washed labeled four-component complex to obtain a measurement C, and    (E) using measurement C as a parameter for evaluating the effect of the treatment.    
   
   
       68 : A method according to  claim 66 , wherein the subject to be evaluated is undergoing allergy vaccination treatment or Specific Allergy Vaccination (SAV) treatment.  
   
   
       69 : A method according to  claim 67 , wherein the subject to be evaluated is undergoing allergy vaccination treatment or Specific Allergy Vaccination (SAV) treatment.  
   
   
       70 : A method according to  claim 66 , wherein the evaluation in step E) is carried out at a number of points in time at the start of and during the treatment period, and that any temporal change, which may be observed, is used as a basis for evaluating and/or predicting the effect of the treatment.  
   
   
       71 : A method according to  claim 67 , wherein the evaluation in step E) is carried out at a number of points in time at the start of and during the treatment period, and that any temporal change, which may be observed, is used as a basis for evaluating and/or predicting the effect of the treatment.  
   
   
       72 : A method according to  claim 66 , wherein the sample antibody is a specific IgE.  
   
   
       73 : A method according to  claim 67 , wherein the sample antibody is a specific IgE.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.